Regeneron Pharmaceuticals Comprehensive Income 2010-2024 | REGN
Regeneron Pharmaceuticals comprehensive income for the quarter ending September 30, 2024 was $0.060B, a 134.05% decline year-over-year.
- Regeneron Pharmaceuticals comprehensive income for 2023 was $-0.081B, a 66.12% decline from 2022.
- Regeneron Pharmaceuticals comprehensive income for 2022 was $-0.239B, a 811.45% increase from 2021.
- Regeneron Pharmaceuticals comprehensive income for 2021 was $-0.026B, a 189.42% decline from 2020.